港股異動 | 內險股集體強勢,中國人壽升近10%,相關衍生品升650%
uSMART友信智投7月6日消息,週一港股,內險股集體強勢,截至11:06分,中國人民保險集團升超11%,眾安線上升超10%,中國太平升超10%,中國人壽升9.88%,新華保險升8.18%。
相關衍生品方面,中壽瑞信零七購A.C(22998.HK)升650%,中壽高盛零七購A.C(23320.HK)升545.45%;人保麥銀零乙購A.C(13135.HK)升207.14%。

消息面上,國泰君安發佈研報稱,受資管新規理財產品淨值化影響,國債收益率上行導致股市無風險利率超預期下降。由於金融板塊整體估值較低,無風險利率下行將修復此前對保險及銀行板塊過度悲觀的基本面預期,引發估值提升機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.